Sara Tolaney
@stolaney1
Followers
11K
Following
22K
Media
374
Statuses
5K
Chief, Division of Breast Oncology @DanaFarber Tennis fan Mother of two teenage girls
Boston. MA
Joined December 2015
Excited to see Destiny Breast 03 now published in NEJM! T-DXd is the current 2L standard of care for metastatic HER2+ breast cancer, and more to come from this agent in the future!. @OncoAlert #bcsm
6
95
367
Incredible review on ER+ disease by @DrHBurstein in NEJM-- with beautiful figures too! #bcsm @OncoAlert #NEJM @DanaFarber
3
95
321
Breathtaking results from DB04 presented by Shaun Modi. Benefit for T-DXd irrespective of subtype & 1+/2+ IHC results . A paradigm shift that breaks through traditional subgroup classification deserving of the standing ovation!!!. #ASCO22 @OncoAlert
1
62
269
DB-03: TDxd dramatically better than T-DM1 (HR 0.28)- complete responses in 16%! New 2L stnd of care. TDxd is revolutionizing outcomes for metastatic HER2+ dz. Brilliant presentation by @JavierCortesMD
3
83
254
KN522: Benefit of pembro seen regardless of stage or nodal status in early stage TNBC. @OncoAlert #SABCS21
2
83
229
RxPONDER: no benefit to chemo in postmenopausal pts 0-3 LNs RS 0-25; premenopausal pts benefited from chemo; 46% decrease in IDFS events; 53% decrease in deaths, 5-year OS absolute improvement of 1.3%; is this impact of suppression of ovarian fxn from chemo? #SABCS20 @OncoAlert
6
89
224
Adjuvant olaparib x 1yr improves iDFS in pts with high risk breast cancer and gBRCAm! .👉3 yr iDFS 85.9% vs 77.1% (HR 0.58)-- absolute difference 8.8%. 👉Genetic testing should be offered to early stage pts @OncoAlert #bcsm.
7
70
218
Positive data for tesetaxel (oral taxane) in metastatic HR+ breast cancer announced! The CONTESSA trial Achieved its Primary Endpoint – Tesetaxel Plus a Reduced Dose of Capecitabine Significantly Improved PFS Versus Capecitabine Alone (Hazard Ratio=0.716; p=0.003; 9.8 vs 6.9 mo).
4
72
203
monarchE: Results from cohort 1 (91% of pts were in cohort 1).HR 0.68.Benefit of adjuvant abemaciclib in high risk HR+ breast cancer seen. @OncoAlert #ESMOBreast2022
2
71
198
TROPICS-02 Overall Survival data now published in The Lancet!. Sacituzumab govitecan improved PFS, ORR, OS, & QOL c/w TPC in pts with pretreated metastatic HR+ BC. Benefit seen across all Trop-2 exp levels. @DFCI_BreastOnc @OncoAlert #bcsm .
2
73
195
Important study: DESTINY-Breast09 looking at TDXd +/- pertuzumab vs THP for 1L therapy of HER2+ MBC; currently enrolling
6
48
192
Who needs adjuvant abemaciclib? A fabulous discussion of this by @AngieDemichele with a fantastic algorithm!. #SGBCC2023 @OncoAlert #bcsm
4
81
185
TROPION-Breast01: Dato-DXd vs TPC in ER+ mBC w/ 1-2 prior lines of chemo . 63% w/1L prior chemo.~80% w/prior cdk 4/6i. PFS 6.9 vs 4.9 mo, HR 0.63, p<0.0001.ORR 36.4% vs 22.9%. Fewer grade >=3 AEs w/Dato-DXd c/w TPC.50% Stomatitis,3% ILD. @OncoAlert #bcsm #ESMO23 @dradityabardia
1
65
171
Monaleesa-2: AI +/- ribociclib for 1L metastatic HR+ breast cancer. Improvement in OS seen (63.9 mo vs 51.4 mo, HR 0.76); OS now exceeds 5 yrs!. @myESMO @OncoAlert
0
48
164
Fabulous discussion by @GrindaThomas including novel bispecifics targeting PD1 or PDL1 + VEGF. @SABCSSanAntonio #SABCS24 @oncoalert
Amazing discussion by @GrindaThomas at the Poster Spotlight Session 3 - Highlights on novel therapeutics at #SABCS24 putting into context novel immunotherapy, anti-VEGF and chemotherapy combinations
0
61
151
Vaccinated! Incredible that vaccines were developed so quickly and wonderful job by @DanaFarber to keep employees safe. Thank you!
3
8
141
The FDA has granted accelerated approval to pembrolizumab for use in combination with chemotherapy in the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 as determined by an FDA-approved test.
2
33
143
RIGHT Choice: OS + AI + Ribo vs combo chemo in premenopausal pts for 1L metastatic HR+ dz with measurable dz + visceral dz. PFS: 24 mo vs 12.3 mo (HR 0.54) favoring OS +AI +Ribo. @OncoAlert #SABCS22 #bcsm
1
55
142
very important news! Overall Survival seen in KN522!!!.
News Direct from Industry:. "KEYNOTE 522 meets OS Endpoint in High Risk Early Stage TNBC #BreastCancer ". "New OS results build on the pathological complete response and event-free survival data previously reported from the KEYNOTE-522 trial". " KEYNOTE522: Pembrolizumab in
0
45
140
I am SUPER EXCITED to see @EMittendorfMD as ASCO president-elect. She is an amazing breast surgeon, scientist, colleague, friend, and leader! This is wonderful for @ASCO!. @DFCI_BreastOnc
3
20
130
SABR-COMET3 to help answer if SBRT improves OS in pts with oligometastatic dz. @OncoAlert #bcsm
2
38
128
PRESS RELEASE from TROPICS-02: Sacituzumab govitecan resulted in a statistically significant improvement in overall survival compared to standard chemotherapy in pretreated metastatic HR+ breast cancer! Great news for patients!. @OncoAlert #bcsm.
0
39
131
KN355: pembro added to chemo improves OS (23.0 vs 16.1 mo, HR 0.73) in CPS≥10 mTNBC in 1L. @myESMO @OncoAlert
1
46
129
FDA approves abemaciclib in the adjuvant setting for HR+ breast cancer!!! Incredible for our high risk patients with HR+ disease!. Interesting that the approval includes Ki67≥20% given benefits seen in pts with both low and high Ki67. #bcsm @OncoAlert .
3
55
124
PALLAS: Final analysis does not find any benefit for adjuvant palbociclib. Incredible effort, and investigators are to be congratulated. So much more to be learned from TransPALLAS. @MichaelGnant @elmayermd @OncoAlert #SABCS21
2
36
125
Wonderful highlights of data in TNBC from SABCS presented by @CCortiMD within @DFCI_BreastOnc in our triple-negative working group
2
31
120
DAISY: Very interesting data on benefits of TDxd in HER2 3+, HER2 low, HER2 0. Is the ~30% ORR in HER2 0 an issue with testing? We need a more quantitative test for HER2. No grade 3-5 ILD. @OncoAlert #SABCS21 #bcsm
4
37
115
Patritumab deruxtecan (HER3 ADC) in metastatic breast cancer that was HER3+ (113 HR+, 53 TNBC, 14 HER2+) ORR HR+ 30%, 23% TNBC, 43% HER2+ HER3 expression dynamic. 6.6% ILD #ASCO22 @OncoAlert
0
28
117
monarchE: ctDNA at baseline + 24 mo in a subset of pts. Detection of ctDNA at baseline soon after completion of neo/adjuvant tx: 10/178 (5.6%).3 of 10 cleared ctDNA + none recurred.7 of 10 had persistence + all recurred. #SABCS23 @OncoAlert #bcsm.
3
32
116
Happy Birthday @PTarantinoMD ! We are so lucky to have you as part of the @DFCI_BreastOnc family!!!
3
1
113
What an amazing breast oncology group! I feel very lucky to be surrounded by such incredible colleagues @DFCI_BreastOnc !
5
13
116
MAINTAIN beautifully designed and presented by @KalinskyKevin looked at the question of continuing cdk 4/6i beyond progression showed ET + ribociclib improved PFS compared to ET, 2.7 vs 5.2 mo, majority with fulvestrant as ET #ASCO22 @OncoAlert.
2
23
111
ER low (1-10%) in early breast cancer in NCDB analysis. 3% of ER+ BC were ERlow.10.362 pts (7,018 recv'd chemo). Endocrine therapy (ET) omission assoc w/ 25% higher risk of death (HR 1.25, 95% CI 1.05-1.48). If pCR, omission of ET --> not significant. #ASCO24 @OncoAlert #bcsm.
4
31
111
PADMA study: ET + palbo vs chemo (cape/taxane/navelbine) in high risk HR+ MBC--> confirms ET+ cdk4/6i is 1L SOC. n=150.42% w/liver mets.6% BRCAm.TTF: 17.2 vs 6.1mo HR 0.46.PFS: 18.7 vs 7.8 mo, HR 0.45.OS trend: 46.1 vs 36.8 mo. #SABCS24 @OncoAlert #bcsm
2
40
112
SITC clinical practice guideline on immunotherapy for the treatment of breast cancer now published online in JITC! Very timely! @JenniferLitton @EmensLeisha @OncoAlert #bcsm .
0
39
105
What an incredible #SABCS23! A special thanks to the superstar @VKaklamani for all are hard work!
3
15
107
Important presentation of the adjuvant aspirin trial in breast cancer by Wendy Chen from @DanaFarber demonstrating no benefit for aspirin therapy in preventing recurrence (HR 1.25). @OncoAlert @DanaFarberNews @DFCI_BreastOnc #bcsm
0
34
107
Incredible work by @AnnPartridgeMD and colleagues to conduct the POSITIVE trial to help us understand the impact of interrupting endocrine therapy to try to conceive--> critical data to help us inform our young breast cancer patients. @DFCI_BreastOnc @OncoAlert.
Finally out in @NEJM results from #POSITIVE trial showing that temporary interruption of #EndocrineTherapy to attempt #pregnancy is safe in #BreastCancer patients: this is wonderful news…super congrats @AnnPartridgeMD @etop_ibcsg et al! @OncoAlert #bcsm.
0
25
106
10 yr f/u data from APT: TH for pts small, node-negative HER2+ BC. 406 pts, 6 distant recurrences, iDFS 91.3%, RFI 96.3%. HER2DX assoc w/ iDFS + RFI. @OncoAlert @DFCI_BreastOnc .
1
30
107
An important study by @EMittendorfMD . Of those with clinical node- TNBC ~10% of T1ab tumors, + ~15% of T1c tumors will be node + at surgery. Important implications for who needs preop tx + pembro. Consider axillary US in these pts. @OncoAlert .
4
37
103
OlympiA: 1 yr of adj olaparib resulted in significant improvement in iDFS and DDFS in gBRCA high risk breast cancer; while OS not yet significant, very impressive. No excess MDS/AML (0.2% vs 0.3%); no impact on Global QOL scores. Amazing global effort! . @OncoAlert #bcsm #ASCO21
0
32
99
Congratulations @DrEricWiner. You have built an outstanding breast oncology program @DanaFarber and have been an incredible mentor to so many. You will be very missed by us all. We know we will continue to see great things from your leadership @YaleCancer. #bcsm @OncoAlert.
We are proud to announce @DrEricWiner as Director @YaleCancer and Physician-in-Chief @SmilowCancer. Dr. Winer is an internationally renowned expert in breast cancer and president-elect of the American Society of Clinical Oncology @ASCO. @YaleMed @YNHH .
1
10
102
FDA grants regular approval to sacituzumab govitecan for mTNBC with ≥2 lines of chemo (at least 1 for metastatic dz)-- great news that this expands the label! So important for pts! #bcsm @OncoAlert
1
36
100
Congratulations @DrChoueiri and @KimmieNgMD -- two incredible people who will be fabulous on the ASCO Board!!. @DFCI_BreastOnc @DanaFarber_GU.
🗞️ Great news from the @ASCO elections! Congrats to @DrChoueiri for being elected to the ASCO Board of Directors and to @KimmieNgMD for being elected member of the Nominating Committee! @DanaFarberNews @DanaFarber
6
10
101
INAVO120 phase 3 study is positive.Fulvestrant + palbociclib +/- inavolisib (oral PI3Ki) in 1L metastatic HR+ breast cancer that progressed on or within 12 mo of adjuvant endocrine therapy in pts with a PI3Km met its primary endpt of PFS. @OncoAlert #bcsm.
2
26
100
KATHERINE Final iDFS and 2nd interim OS Analysis . Adj T-DM1 vs H in pts with RD after preop HER2-directed therapy. f/u 8.4 yrs. iDFS: HR 0.54, absolute benefit 13.7%.OS: HR 0.66, absolute benefit 4.7%, statistically significant p=0.0027. @DFCI_BreastOnc #SABCS23 @OncoAlert
1
39
100
Very big news! KN522 meets EFS endpoint!! Wonderful that we can improve outcomes for early stage TNBC pts. While there are still unanswered questions (which pts should get IO, what is the optimal chemo backbone, is adjuvant IO needed), this is practice changing! @OncoAlert #bcsm.
Merck Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival (EFS) in Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) -
3
32
100
In pts w/ HR+ mBC (with HER2low, or HER2 ultralow dz) TDXd led to a significant ⬆️ in PFS c/w TPC. Press release out from DESTINY-Breast06. Will be very interested to see the data; will have profound impact on tx sequencing + could put an end to HER2low as a biomarker.
NEWS FROM INDUSTRY.Results from the DESTINY-Breast06 trial indicate that trastuzumab deruxtecan🧪could become a new standard of care for #HER2 -low 🧬and HER2-ultralow metastatic #BreastCancer patients. ➡️showing significant PFS improvements 📈over standard chemotherapy after
3
35
97
Fantastic discussion of APHINITY by @JavierCortesMD suggesting a clear benefit for pertuzumab in node + HER2+ BC with improvement in iDFS (4.9% delta) & trend to OS (HR 0.80). In the future, maybe biomarker approaches can help us tailor-- HER2Dx may do this. @OncoAlert #bcsm
6
38
99
Outcomes from PALLAS for Stage IIA ER+ BC. 4 yr iDFS 92.9% vs 92.1%. No benefit for the addition of palbociclib to endocrine therapy at median f/u 50 mo; very good outcomes in both arms. @AngieDemichele @elmayermd #asco #bcsm.@DFCI_BreastOnc
1
38
94
Incredible effort to look at pregnancy and outcomes in pts with BRCAm . Pregnancy without impact on recurrence particularly in pts with BRCA1m. @Oncoalert #SABCS23 @matteolambe
0
20
82
Jose Baselga made such an incredible impact on drug development and this work impacted the lives of many patients. He also played a key role in mentoring many junior faculty members and helped build many careers. A significant loss. Thoughts are with his family.
Prof. José Baselga has passed on March 21st. Dr.Baselga was an amazing oncologist& researcher who paved the way for many molecular targeted therapies. in2017 was awarded the @myESMO Lifetime Achievement Award. Huge loss for the Oncology Community.Our thoughts are with his family
1
10
96
Data from ATEMPT published in JCO:.*3 yr iDFS for 1 yr of T-DM1 in stage I HER2+ BC: 97.8%.*No difference in rate of clinically relevant toxicities between 1 yr of T-DM1 vs TH.*PROs suggest less neuropathy+ alopecia and better QOL with T-DM1. . @OncoAlert.
7
41
95
And the debate begins: should we do local therapy in the setting of metastatic breast cancer?. Pro: Dr. Badwe takes this on (despite the TATA Memorial study showing no benefit in PFS or OS). #SGBCC2023 @OncoAlert #bcsm
4
31
94
Phase Ib Study of Ribociclib Plus Fulvestrant and Ribociclib Plus Fulvestrant Plus PI3K-Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer: Unable to find a tolerable RP2D for triplet combinations with PI3Ki due to tox #bcsm
1
43
91
Impressive pCR benefit seen in IMP031 regardless of PD-L1 status with the addition to atezo to anthracycline + taxane chemotherapy (no platinum in backbone); study won't be powered adequately for EFS, and still waiting on KN522 final EFS data @EMittendorfMD @OncoAlert #ESMO20
2
38
93
Data on retreatment with TDXd after grade 1 ILD from a pooled analysis presented by @hoperugo demonstrates that 67% retreated without ILD recurrence. #ESMOBreast24 @OncoAlert #bcsm
0
31
95
PHERGain beautifully presented by @JavierCortesMD :.80% with preop HP had early PET response, 38% w/ pCR . 95.4% iDFS for the HP arm. 3 yr iDFS for those pts w/o chemo (n=86) 98.8%. Early PET response seems to help de-escalate therapy in early HER2+ disease. @OncoAlert #ASCO23.
1
42
94
RxPONDER: AMH (low levels associated w/ diminished ovarian reserve) in women classified as premenopausal. If low AMH --> no benefit from adj chemo .If med/high AMH--> ⬆️4.4% in 5 yr DRFS w/ chemo. Suggests:chemo impact may be due to impact on ovarian fxn. @OncoAlert #ASCO24.
0
35
95
POSITIVE: interruption endocrine tx to attempt pregnancy. n=518.94% recovered menses, most resumed during the first 6 months.51% underwent fertility preservation at BC diagnosis.43% underwent ART .No increase in breast cancer events in pts undergoing IVF. #SABCS23 @OncoAlert
0
28
93
INAVO120: Fulv + palbo +/- inavolisib in HR+ MBC w/relapse on or w/i 1 yr of adj ET --> impressive data. PFS: 15.0 vs 7.2 mo HR 0.43 , p<0.0001.OS trend HR 0.64.58.6% hyperglycemia (5.6% g3-4).51.2% stomatitis (5.6% g3-4).25.3% rash (g3-4). @jhaveri_komal @OncoAlert #SABCS23
2
38
91
DESTINY-Breast 03 TDXd vs T-DM1.OS median not reached in either arm, but statistically significantly better with TDXd (HR 0.64).mPFS 28.8 mo vs 6.8 mo .ORR 78.5% vs 35%.CR 21% vs 9.5%. ILD 15.2% (no grade 4/5 events). Great presentation by Sara Hurvitz. @OncoAlert #bcsm #SABCS22.
2
22
89
Ian Krop beautifully puts DB06 in perspective. Suggests:.TDXd should be first-line chemo for pts with symptomatic disease, and short DFI after adj tx. Better HER2 testing assays are needed . Work needed to evaluate TDXd in HR- HER2ultralow. @OncoAlert #ASCO24.
1
29
92
Congratulations to @nlinmd on receiving the MSCO Distinguished Researcher Award! Nancy has revolutionized therapy for patients with breast cancer brain metastases and this so well deserved! @DFCI_BreastOnc
10
13
90
Brilliant discussion by @curijoey on KN522.Adding preop pembro to chemo in TNBC improves pCR and EFS, but risk for long term toxicity.Which pts really need preop checkpoint is a critical question?. #ESMOVirtualPlenary @OncoAlert #bcsm
0
29
88
Abemaciclib has activity in HR+ brain mets; intracranial CBR 24% in heavily pretreated pts + drug levels in CSF/CNS met similar to plasma #bcsm
2
34
91
Congrats to @PTarantinoMD! Wonderful commentary on the limited role for anthracyclines in early stage HER2+ breast cancer. @curijoey @JavierCortesMD .
0
23
85
NATALEE: Adj ribociclib for ER+ BC .iDFS now with 33 mo of f/u.43% completed 3 yrs of ribo.35.5% with early discontinuation.20.7% still on ribociclib.Improvement in iDFS: 90.7vs 87.6% HR 0.749, p=0.0006. @OncoAlert #SABCS23
5
21
90
Exciting press release: TROPICS-02 met it primary endpoint in pretreated HR+ metastatic breast cancer. Sacituzumab govitecan led to a significant improvement in PFS c/w TPC!. #bcsm @OncoAlert.
1
25
87
Press release just out: monarchE demonstrates adding abemaciclib to endocrine therapy in the adjuvant setting improves outcomes-- wonderful news for patients!!.
3
20
88
An honor to give the Gabriel Hortobagyi lecture at MD Anderson today- what an incredible group!
1
11
88
Beautiful discussion putting the inavolisib data into context by @hoperugo . Impressive to get this data out so quickly!. @OncoAlert #SABCS23
1
20
86
Beautiful presentation by @elmayermd of the PACE trial looking to address continuation of palbociclib beyond progression on prior CDK 4/6i. No improvement in PFS seen: 4.6 mo vs 4.8 mo. Interesting signal for fulvestrant + palbo + avelumab (PFS 8.1 mo). @OncoAlert #bcsm #SABCS22
4
23
86
Real-world assessment of TDXd-related ILD. 67/600 pts developed ILD (central adjudication).Median time to onset-- cycle 7, 83 d (60d in breast pts).Median 3 prior lines of tx .49% g1, 31% g2, 9% g3, 1.5% g4, 9% g5.29.5% rechallenged, 42.9% relapsing w/ILD. @OncoAlert #ESMO24
3
43
89
BEGONIA: Dato-DXd + Durvalumab in mTNBC update. ORR 79%.mPFS 13.8 mo.>80% with low PDL1 expression (by SP263 or 22C3). Can IO lead to benefit even in PDL1- tumors when combined with a potent ADC?. #ESMO23 @OncoAlert #bcsm.
0
34
87
FDA broadens label for adjuvant abemaciclib, removing Ki67 score for patient selection!. Great news, and makes sense given benefit seen irrespective of Ki67 in monarchE. @OncoAlert #bcsm .
0
24
86
Great presentation by @prat_aleix on intrinsic subtype + outcomes to ribociclib in mHR+ disease; subtype is an independent prognostic factor; HER2E/lumB/lum A all benefit, basal-like does not; HER2E had greatest relative risk reduction #SABCS20 @OncoAlert
4
21
83
Gilead announces planned ph 3 trial trial of sacituzumab + pembro vs chemo + pembro in 1L mTNBC-- great that there is work planned to help get sacituzumab to patients in earlier lines of therapy. #bcsm.
1
22
84
An important day to remind us about the importance of continuing to work towards improving outcomes for our patients with cancer. @OncoAlert #bcsm
0
13
85
PATINA: 1L maintenance HP +ET +/- palbo in ER+ HER2+ BC . n=518 .72% had prior tx for early-stage dz. PFS 44.3 vs 29.1 mo, HR 0.74, p=0.0074.median f/u 52.6 mo.OS 74% vs 29.8% at 5 yrs. Amazing benefit!!!! Congrats to @Otto_DFCI + team!. #SABCS24 @oncoalert @DFCI_BreastOnc.
2
29
87
Congratulations to @AnnPartridgeMD of @DFCI_BreastOnc for the 2023 Giants of Cancer Care award! She has really helped us understand optimal treatment for young women with breast cancer!! Very well deserved!.
Congratulations to @AnnPartridgeMD of @DanaFarber for being our 2023 Giants of Cancer Care winner in Breast Cancer! #bcsm #GiantsCC23
1
9
79
Discussion on HER2CLIMB-02 by Valentina Guarneri leaving us with the question of what the optimal sequencing is for our patients with metastatic HER2+ BC. @OncoAlert #SABCS23
1
32
83
Lots of work is ongoing with ADCs for mTNBC- with new studies for sacituzumab in the 1L setting . #ESMOBreast22 @OncoAlert #bcsm
0
27
80
Beautiful presentation by @nlinmd on OP-1250 (palezestrant) in HR+ mBC.RP2D . 42% >= 3L prior tx.CBR 40%.PFS 4.6 mo (5.6mo ESR1m). @OncoAlert @DFCI_BreastOnc #ESMO23
1
33
80
Excellent poster discussion by @antgiorda including discussion of OS subgroup data from KN522 (poster by @RebeccaDSing ). @SABCSSanAntonio #SABCS24 @DFCI_BreastOnc @OncoAlert
2
25
82
Outstanding presentation by @AnnPartridgeMD on the POSITIVE data looking at outcomes for women w/HR+ BC holding adjuvant ET to try to conceive. Temporary interruption does not impact short-term disease outcomes (median f/u 41 mo). @OncoAlert @DFCI_BreastOnc #SABCS22 #bcsm
0
20
78
Excellent discussion by @prat_aleix on 1L treatment approaches in HER2+ BC and if there is a role of ADCs in preop HER2+ dz. More work ongoing for ADCs in 1L mHER2+ BC(DB09) and for preop HER2 + disease (DB11). @SABCSSanAntonio #SABCS24
3
29
80
Sacituzumab Govitecan has ORR 31%, PFS 5.5 mo in pretreated mHR+ breast cancer. Awaiting data now from TROPICS-02. @KalinskyKevin @ABhealer108 #bcsm.
1
18
80
Excellent discussion of systemic therapy management of gBRCA pts by Andrew Tutt . @SGBCC2023 #bcsm @OncoAlert
1
33
79
World Cancer Day is a reminder of how much we can do together to fight cancer and improve outcomes for our patients.@OncoAlert @DanaFarberNews
1
9
79
ASCENT: benefit with SG versus TPC is irrespective of level of Trop-2 expression; higher efficacy outcomes in pts tx'd with SG with medium/high Trop-2 H-score (vs low Trop-2 H-score) versus those treated with TPC; SG benefit regardless of gBRCA status #SABCS2020 @OncoAlert
1
22
76
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0 ---now online in JCO. Thanks to all the hard work in the NCI breast working group on this! @LGM_Biostats @OncoAlert #bcsm .
0
36
76
Impressive results for sacituzumab in the ASCENT trial: HR 0.41 for PFS when c/w SOC in mTNBC (and improved OS, ORR)
2
28
77
Very helpful discussion by Cristina Saura on how to think about adjuvant therapies in pts with gBRCAm. Could we consider sequential adjuvant abemaciclib after olaparib in high-risk pts with ER+ BC and gBRCAm?. @oncoalert #bcsm #ESMOBreast24
1
21
78
Tucatinib penetrates the CSF with similar drug levels in CSF and plasma-- important for patients with brain metastases. Will be important to learn if this agent can also prevent new brain mets. @OncoAlert #ASCO21.
Congrats to Drs. Erica Stringer-Reasor, Barbara O'Brien, @rashmikmurthy for @theTBCRC study 049: Tucatinib + cape + tras for HER2+ LMD. 1st demonstration of tucatinib penetration into CSF, median CSF:plasma ratio 0.83 at steady state. Study still enrolling-NCT03501979 #ASCO21
0
22
71
